Medical Cannabis Legalization: No Contribution to Rising Stimulant
Rates in the USA
This study aimed to determine if MC legalization increased prescription
stimulant distribution.
Methods Information on the distribution of methylphenidate, amphetamine,
and lisdexamfetamine for 2006 to 2021 was extracted from the Drug Enforcement
Administration’s comprehensive database and the three-year
population-corrected slopes of stimulant distribution before and after MC
program implementation were compared.
Results We found a significant main effect of time
(p<0.001); however, contrary to the hypothesis, the sales status
of states�...
Source: Pharmacopsychiatry - October 26, 2023 Category: Psychiatry Authors: Alexander, Garrett D. Cavanah, Luke R. Goldhirsh, Jessica L. Huey, Leighton Y. Piper, Brian J. Tags: Original Paper Source Type: research
A Convolution ‐based In Vitro‐In Vivo Correlation (IVIVC) Model for Methylphenidate Hydrochloride Delayed‐release and Extended‐release Capsule
(Source: CPT: Pharmacometrics and Systems Pharmacology)
Source: CPT: Pharmacometrics and Systems Pharmacology - October 21, 2023 Category: Drugs & Pharmacology Authors: Pawan Kumar Gupta,
Bev Incledon,
Jogarao V. S. Gobburu,
Roberto Gomeni Tags: ARTICLE Source Type: research
The following article for this Special Issue was published in a different issue. They can be found in their respective issue
Increased sperm deoxyribonucleic acid damage leads to poor embryo quality and subfertility of male rats treated with methylphenidate hydrochloride in adolescence.ANDR. 2022; 10(8): 1632 –1643.https://doi.org/10.1111/andr.13277 (Source: Andrology)
Source: Andrology - October 19, 2023 Category: Urology & Nephrology Tags: ORIGINAL ARTICLE Source Type: research
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients
Expert Rev Neurother. 2023 Oct 17:1-9. doi: 10.1080/14737175.2023.2265068. Online ahead of print.ABSTRACTINTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is a common neurobehavioral disorder with symptoms that may persist in up to 90% of adults diagnosed during childhood and continue to cause significant impairment throughout the lifespan. In the United States (US), amphetamine and methylphenidate formulations have been available to treat ADHD for several decades. Only one nonstimulant, atomoxetine, was available for the treatment of ADHD in adults until recently. In April 2022, a second nonstimulant, viloxazi...
Source: Expert Review of Neurotherapeutics - October 17, 2023 Category: Neurology Authors: Ann Childress Robert Sottile Sherine Khanbijian Source Type: research
